- Country: USA
- Summary: Pre-Clinical Biomarker Qualification Study for MSX Metagenie ASD Diagnosis Aid
- UST Ref No: 134080441
- Deadline: 28 Feb 2026
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: MSX2026_US_PC01
- Purchaser's Detail:
- Description:
- Objective of This Tender: To select a qualified CRO to execute a prospective, IRB-approved, IDE-exempt (21 CFR 812.2(c)(3)) specimen collection study in US that: • Recruits 550 pediatric subjects (1-13 years) across diverse U.S. regions • Collects stool specimens under standardized, controlled conditions • Generates high-quality, audit-ready data to assess biomarker generalizability • Informs final biomarker panel selection for the pivotal De Novo Clinical Performance Study
- Documents:
Purchaser : MicroSigX Biotech Diagnostic Limited
12/F., 208 Johnston Road, Wanchai,
Hong Kong
Contact Number: +852 2903 0717
Email :tender@microsigx.com
URL :www.microsigx.com
Pre-Clinical Biomarker Qualification Study for MSX Metagenie ASD Diagnosis Aid - USA Tender
The MicroSigX Biotech Diagnostic Limited, a Government sector organization in USA, has announced a new tender for Pre-Clinical Biomarker Qualification Study for MSX Metagenie ASD Diagnosis Aid. This tender is published on USARFP under UST Ref No: 134080441 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2026-02-28.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
